Abstract: Colistin is a polymyxin antibiotic used to treat patients infected with multidrug-resistant Gram-negative bacteria (MDR-GNB). The objective of this work was to develop a whole-body physiologically based pharmacokinetic (WB-PBPK) model to predict tissue distribution of colistin in rat. The distribution of a drug in a tissue is commonly characterized by its tissue-to-plasma partition coefficient, K p . Colistin and its prodrug, colistin methanesulfonate (CMS) K p priors, were measured experimentally from rat tissue homogenates or predicted in silico. The PK parameters of both compounds were estimated fitting in vivo their plasma concentration-time profiles from six rats receiving an i.v. bolus of CMS. The variability in the data was quantified by applying a nonlinear mixed effect (NLME) modelling approach. A WB-PBPK model was developed assuming a well-stirred and perfusion-limited distribution in tissue compartments. Prior information on tissue distribution of colistin and CMS was investigated following three scenarios: K p was estimated using in silico K p priors (I) or K p was estimated using experimental K p priors (II) or K p was fixed to the experimental values (III). The WB-PBPK model best described colistin and CMS plasma concentration-time profiles in scenario II. Colistin-predicted concentrations in kidneys in scenario II were higher than in other tissues, which was consistent with its large experimental K p prior. This might be explained by a high affinity of colistin for renal parenchyma and active reabsorption into the proximal tubular cells. In contrast, renal accumulation of colistin was not predicted in scenario I. Colistin and CMS clearance estimates were in agreement with published values. The developed model suggests using experimental priors over in silico K p priors for kidneys to provide a better prediction of colistin renal distribution. Such models might serve in drug development for interspecies scaling and investigate the impact of disease state on colistin disposition.
Polymyxins are a group of active polypeptide antibiotics that were discovered in the mid-20th century, with colistin first isolated in 1950 [1] . The major moieties of colistin, or polymyxin E, are colistin A and B differing in the structure of their N-terminal fatty acyl group. The use of colistin was largely abandoned in the 1970s due to nephrotoxicity and neurotoxicity as well as the availability of antibiotics with a better safety [1] . In the 2000s, because of a dramatic increase in the incidence of wide resistance spectra Gram-negative bacteria such as Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella pneumonia, colistin has become one of the lastline treatment options for critically ill patients. Recent pharmacokinetic (PK) studies based on plasma concentrations have led to new dosing recommendations of colistin [2] [3] [4] . There is, however, a lack of knowledge on tissue distribution of colistin, which is of importance to better understand bacterial killing at the sites of infection.
In clinical practice, colistin is parenterally administered as colistin methanesulfonate (CMS) sodium that is an inactive prodrug devoid of antimicrobial activity. In CMS, the amino groups of the aminobutyric acids forming the side chain of colistin are derivatized with methanesulfonate moieties. In vitro and in vivo, CMS is converted into colistin via spontaneous aqueous hydrolysis [1, 5] . The development of sensitive and specific analytical methods to assay colistin and CMS [5, 6] enabled in vitro [5, 7] and in vivo PK studies, both in humans [8, 9] and in animals [10] [11] [12] . The results of these studies have importantly increased the knowledge and the understanding of colistin and CMS PK.
One of the challenges to be addressed in order to optimize the clinical use of colistin is to characterize its distribution in tissue. Because bacterial infections are mostly occurring in the interstitium rather than in plasma, the use of a target plasma exposure instead of a target time course of interstitial antibiotic concentration may lead to treatment failures [13, 14] . In 1973, Craig et al. [15] studied the distribution of polymyxins in rabbit tissues. Even though it is difficult to quantitatively interpret the results of this work, due to the microbiological analytical assay used, it is of value to notice that tissue binding of polymyxins was found to be the major determinant of their distribution and accumulation within the body.
Whole-body physiologically based pharmacokinetic (WB-PBPK) models have gained popularity as appealing tools during the last decade with increasing application in drug development and regulatory science [16, 17] . WB-PBPK models are used to predict drug concentrations in tissue, to scale PK from animal to human, and to predict the influence of pathophysiological changes on drug disposition [18, 19] . WB-PBPK models include the volumes of the major tissues associated with the respective regional blood flows and tissueto-plasma partition coefficients. The K p for a non-eliminating tissue is defined as the ratio of the concentration of the drug in the tissue at steady state over its corresponding concentration in plasma. Animal tissue data are traditionally used to experimentally determine K p . However, such experiments require a high number of animals, raising ethical and costrelated questions. This led to the development of in silico models to predict K p . These in silico models are either empirical (e.g. correlation-based) [20] or physiological [21] and take into account the physicochemistry and protein-binding properties of the compound as well as the tissue composition. Traditionally, WB-PBPK models are used in simulation mode to predict concentration-time profiles of drugs from in vitro and in silico prior data, whereas parameter estimation is mainly performed using data-driven empirical compartmental models. In the last decade, a few studies have used a physiologically based PK approach to estimate PK parameters [22] [23] [24] . Tsamandouras et al. [23] advocate the application of PBPK models fitting plasma PK profiles with parameter estimation incorporating in vitro, in silico and observed in vivo data.
The aim of this work was to develop a WB-PBPK model for colistin and its prodrug CMS capable of describing their respective plasma observed data and predicting tissue concentration-time profiles in rats. For this purpose, three scenarios were compared as follows: estimating K p using in silico priors (I), estimating K p using priors from rat tissue homogenate experiments (II) and K p fixed to the experimental values (III).
Materials and Methods
Chemicals. CMS (Colymicine 1 MU; Sanofi Aventis, Paris, France) was kindly provided by the pharmacy of the Poitiers University Hospital (Poitiers, France), and colistin sulphate was obtained from Sigma (Sigma, Saint-Quentin-Fallavier, France). Colistin methanesulfonate and colistin were presented as lyophilized powder and were reconstituted in 0.9% NaCl prior to intravenous (i.v.) administration. All chemicals were of analytical grade and solvents of high-performance liquid chromatography (HPLC) grade.
Animals. Male Sprague Dawley rats were used in both the tissue homogenates study (n = 6) and the in vivo PK study (n = 6). Rats were purchased from Janvier Laboratories (Le Genest-St-Isle, France) and weighted between 280 and 350 g at the start of the experiments. The animals were acclimatized in wire cages in a 12-hr light-dark cycle for a minimum of 5 days before the start of the experiments and had free access to food (A03, Safe; Villemoisson-sur-Orge, France) and water during the experiments. All procedures applied during the dosing and the sampling steps were in accordance with the Principles of Laboratory Animal Care (National Research Council 2011 Guide for the care and use of laboratory animals, 8th ed. National Academies Press, Washington, DC, USA) under license No. 86051.
In vivo PK study. The PK data were obtained from a previously published study [10] in which CMS had been administered through an i.v. bolus in the left femoral vein at the dose of 15 mg/kg of body weight. Arterial blood was sampled at 0, 5, 15, 30, 60, 90, 120, 150 and 180 min. post-dose via the left femoral artery catheter.
Tissue homogenates study.
Implantation of femoral vein and artery catheters. Venous and arterial catheters were implanted the day before the experiments for CMS and colistin administrations using a procedure already described in the literature [25] .
CMS administration. A 3-hr constant i.v. infusion of CMS [8.5 mg/ hr/kg of body weight corresponding to 3.2 mg/hr/kg of colistin base activity (CBA)] [26] was administered via the left femoral vein to reach steady state. Blood was sampled at 2 and 3 hr after the start of the infusion. At the end of the infusion, the rats were anaesthetized by isoflurane 2.5-3% inhalation (Forene, Abbot, Rungis, France), and an intracardiac exsanguination was performed to immediately remove the lungs, brain, heart, fat, muscle, duodenum, liver and kidneys. Plasma was separated by centrifugation and frozen at À20°C until analysis (0-15 days after the end of the experiments).
Colistin administration. A 4-hr constant i.v. infusion of colistin sulphate (0.35 mg/hr/kg of body weight) was administered via the left femoral vein to reach steady state. Blood was sampled at 3 and 4 hr after the start of the infusion. At the end of the infusion, the rats were killed by intracardiac exsanguination, and the tissues were removed as described above. Plasma was immediately separated from the other components of the blood by centrifugation and was frozen at À20°C until analysis.
Tissue homogenates preparation. In addition to entire brains, hearts, lungs and kidneys, a thigh muscle sample, a fat sample from the neck, a random lob of the liver and a segment of the duodenum were collected from each rat. All collected organs were cleaned with saline; duodenum and kidney lumens were flushed to remove the residuals inside. After being weighed, organ samples were freshly prepared as 20% tissue homogenates in PBS (i.e. diluted six times) using a T-18 Ultra-Turrax homogenizer (IKA Werke GmbH & Co. KG, Staufen im Breisgau, Germany). This procedure was carried out on dried ice to minimize the increase in temperature that could favour conversion of CMS into colistin. Tissue homogenates were centrifuged prior to LC-MS/MS analysis. Colistin methanesulfonate and colistin concentrations were assayed in the supernatant.
Analytical method.
Analysis of CMS and colistin in plasma. Colistin methanesulfonate and colistin concentrations in plasma were determined using a previously published high-performance liquid chromatography-tandem mass spectrometry (LC-MS/MS) method [6] .
Analysis of CMS and colistin in tissue homogenates. A similar HPLC-MS/MS method [6] was applied to determine CMS and colistin concentrations in tissue homogenates as in plasma using a volume of 200 lL of tissue homogenates mixed with 50 lL of plasma. Calibration curves were constructed between 10 and 0.0097 lg/mL, and three levels of controls were tested -3.75, 0.625 and 0.156 lg/mL. The interday precision was higher than 93%, and the bias was lower than 7% (n = 32). To test the sample preparation method, blank tissue homogenates for each tissue were overloaded with colistin at a concentration of 5 lg/mL and thereafter extracted (n = 5). Intraday precision was higher than 90%, and the bias was lower than 11%.
Whole-body physiologically based pharmacokinetic (WB-PBPK) model.
Clearance of CMS.
Most of the administered CMS is renally excreted (CL r-CMS ) through glomerular filtration and tubular secretion [1, 27, 28] .
In the WB-PBPK model, CL r-CMS was expressed as a linear function of the average glomerular filtration rate (GFR) in rat (table 1) in which the slope parameter, Slope CMS , was estimated. The average GFR value in rat was collected from the literature data (table 2) . The remaining CMS is eliminated through spontaneous aqueous hydrolysis forming colistin. In the WB-PBPK model, the conversion of CMS into colistin was assumed to take place in all tissues, plasma and urine at the same rate. This assumption was based on in-house ex vivo stability experiments in rat tissue homogenates at 22°C (Appendix 1) where hydrolysis kinetics of CMS was comparable across tissues. The derived hydrolysis clearance of CMS (CL hyd-CMS ) was expressed as the sum of the hydrolysis intrinsic clearances (CL hyd-CMS-int ) in each tissue (table 1) which were the product of k hyd-CMS and the physiological volume of the tissue of interest (V tissue ). Different mathematical models were evaluated to characterize the kinetics of CMS hydrolysis: linear, time or colistin concentration-dependent.
Clearance of colistin. Colistin is non-renally eliminated [1, 2, 27] , and different alternatives were tested to estimate its clearance: hydrolysis, hepatic and/or biliary eliminations. The hydrolysis was assumed linear and to occur at the same rate (k nr-coli ) in all tissues, plasma and urine. The derived non-renal clearance of colistin (CL nr-coli ) was expressed as the sum of the intrinsic clearances (CL nr-coli ) in each tissue (table 1) which were computed as the product of k nr-coli and V tissue (table 1). In addition, a tubular reabsorption clearance of colistin (CL rea-coli ) was set to nine times the urinary flow rate (UFR; table 1). This was based on findings from a study using an isolated perfused kidney model which demonstrated that more than 90% of colistin formed in urine from renally excreted CMS was reabsorbed [29] . The average UFR value in rat was collected from the literature data (table 2) .
Plasma protein binding. No data on CMS unbound fraction in plasma (f up-CMS ) were available in the literature. Therefore, f up-CMS was predicted to be 0.75 using the online Simcyp prediction tools [30] accounting for the physicochemical properties of CMS (pKa1 = À4.3, pKa2 = 6.46 and logP = À1.2) [31] . The unbound fraction of colistin in plasma (f up ) was set to 0.44, a value reported in the literature [32] .
Tissue-to-plasma partition coefficients (K p ). For non-eliminating organs, K p is defined as the ratio between tissue and plasma concentrations at steady state of a given compound [33] . In this work, three scenarios were tested to estimate CMS and colistin K p . In scenario I, K p values were estimated for all tissues using in silico priors predicted using the model developed by Bj€ orkman et al. [21] . This model is based on the physiological description of tissues (Equation 1) and accounts for the binding properties of the molecules. CMS and colistin are not penetrating into the cells [5] , and therefore, the terms related to the distribution into the erythrocytes and the tissue cells were ignored in the equation.
where PV f is the plasma volume fraction, IV f the interstitial volume fraction, r a the interstitium:plasma albumin ratio and f up the unbound fraction in plasma.
In scenario II, K p priors implemented in the WB-PBPK model were obtained from the rat tissue homogenates study. For each tissue, a specific K p was calculated, for both CMS and colistin, as the ratio of the concentration in the tissue homogenate over the corresponding plasma concentration at steady state. In scenario III, the experimental K p values were fixed without being re-estimated in the WB-PBPK model. CMS and colistin K p for skin and spleen were not measured in the rat tissue homogenates study. Therefore, in scenarios II and III, they were set to the in silico K p priors. In all scenarios, CMS and colistin K p for carcass were calculated as the average of all the K p of the tissues in the WB-PBPK model. K p estimates were also corrected to account for the clearance processes taking place in the tissues for the two compounds as shown in Equation (2):
where K p-tissue is the estimated K p for a given tissue, K p-prior-tissue , the in silico or experimental K p prior, Q tissue the tissue-specific regional blood flow and CL int-tissue the intrinsic clearance in the tissue of interest for either CMS or colistin.
To avoid model over-parameterization, tissues were grouped together based on their prior equilibration kinetic rate constant (K T-tissue ) [34] . For all scenarios, K T-tissue was calculated for each tissue as in Equation (3). 
where Q tissue is the regional blood flow, K p-prior-tissue the prior value of the tissue-to-plasma partition coefficient and V tissue the physiological volume of the tissue of interest. For each group of tissues, a proportionality factor (F GR ) was estimated and multiplied to the K p priors of each tissue of the group (table 1) . Thereafter, K p estimate for each tissue was derived (table 1) . The volumes of distribution at steady state of CMS and colistin (V ss-CMS and V ss-coli ) were calculated from the K p estimates as shown in table 1.
In scenarios I and II, K p priors were incorporated in the WB-PBPK model using the normal inverse Wishart prior subroutine (NWPRI) in NONMEM 7.3 [22, 35] . In scenario I, different degrees of uncertainty on the in silico K p priors (relative standard error; RSE%) were tested, whereas in scenario II, the uncertainty on the experimental K p priors was derived from the experimental variability (i.e. S.E. ¼ S.D. ffiffi ffi n p , S.D.
being the experimental standard deviation and 'n' the number of samples, here 6).
Model structure. The generic WB-PBPK model structure for CMS and colistin in rats is depicted in fig. 1 . Eleven tissues including lungs, brain, heart, skin, adipose, muscle, spleen, gastrointestinal tract (GIT), liver and kidneys were represented as compartments and linked together by the arterial and venous blood compartments in a closed loop format. The carcass compartment accounted for all remaining tissues that were not included in the generic model structure. The mass transfer to the tissue compartments was assumed perfusion-limited, and the drug was considered uniformly distributed (i.e. well-stirred distribution) in each tissue compartment. The urinary tract (UT) system was simply described as one compartment representing the kidney tubules. For CMS, the kidney tubules were linked to the kidney tissue via the renal clearance of CMS. For colistin, the kidney tubules were linked to kidney tissue via the tubular reabsorption clearance of colistin. Both CMS and colistin were assumed to be excreted from the kidney tubules via the urinary flow ( fig. 2 ). Each tissue compartment was associated with a specific physiological regional blood flow, a physiological volume and a K p . The measured body weight of each animal was structurally implemented to calculate the individual Q tissue and V tissue using the data available in the literature [19, 36, 37] . The differential equations driving the mass transfer of CMS and colistin in the model compartments are displayed in Appendix 2.
Population pharmacokinetic modelling. The dose and the concentrations were converted into molar units to account for the fact that one molecule of CMS (MW: 1631.9 g/mol) [10] is hydrolysed into one molecule of colistin (1166.6 g/mol) [10] . Firstly, a sequential modelling approach was applied where the models were fitted to the CMS plasma data only; thereafter, CMS parameters were fixed when colistin parameters were estimated using colistin plasma data. In a second step, a simultaneous modelling approach was applied where all parameters were estimated simultaneously based on all the plasma concentration-time data of CMS and colistin. The log-transformed concentrations were used in the modelling to facilitate the numerical calculation.
The PK of CMS and colistin was analysed using a nonlinear mixed effect (NLME) modelling strategy characterized by a structural model including the fixed effects and a stochastic model accounting for the random effects. The random effects were the interindividual variability (IIV) assigned to specific parameters and the residual unexplained variabililty (RUV) primarily describing the experimental variability and assigned to the observed plasma concentrations. The IIV was assumed to follow a log-normal distribution as shown in Equation 4:
where h i is the individual parameter value, h is the typical population value and ƞ i is the patient-specific random effect following a normal distribution with mean zero and variance x 2 . The values of h and x 2 were estimated in the model. Different RUV models with additive, proportional and combined errors (i.e. additive + proportional) were evaluated. CMS and colistin plasma were assayed at the same time points from the same blood sample; therefore, the L2 data item method in NONMEM was used to Data are from the literature [19, 21, 36, 37] . 1 As CMS and colistin were assumed to not distribute into the red blood cells, haematocrit was used to derive the blood/plasma ratio (R bp ):
investigate whether there was a correlation between their RUV [38] . Model selection was based on the physiological plausibility and on the maximum-likelihood statistics, which is quantified by the objective function value (OFV). The OFV is defined as minus two times the loglikelihood. A 5% significance level was applied for statistical test, that is the more complex model was selected when the reduction in OFV (dOFV) was at least 3.84 (corresponding to a p-value <0.05 for 1 degree of freedom). The performance of the model was evaluated using goodness-of-fit plots and visual predictive checks (VPC), in which 1000 replicates were simulated using the original data set as a template. Eta shrinkage was continuously monitored throughout the model development [39] , and sampling importance resampling (SIR) methodology [40, 41] was utilized to obtain the standard errors of the parameters estimates (SIR settings: five iterations with 1000, 1000, 1000, 2000, 2000 samples and 200, 400, 500, 1000, 1000 resamples for each).
Predicted tissue distribution for CMS and colistin. The WB-PBPK model developed in this work was used to predict colistin unbound concentration-time profiles in tissues accounting for the variability in the data and uncertainty in the parameter estimates (n = 200). Model predictions were utilized to illustrate the outcomes in the investigated scenarios (I, II, III). Colistin unbound concentrations in tissue (C ut ) were derived from the WB-PBPK model parameters as follows ( Equation 5):
where f up is the plasma unbound fraction of the compound of interest, K p-tissue the estimated K p and C p the total plasma concentration. 
Results
Tissue homogenates study. Plasma concentrations of CMS at 2 hr and 3 hr after the start of the constant infusion of CMS were 15.1 AE 4.3 lg/ mL and 14.2 AE 3.7 lg/mL, respectively. Colistin plasma concentrations at 3 and 4 hr after the start of the constant infusion of colistin sulphate were 0.8 lg AE 0.1 lg/mL and 0.9 AE 0.1 lg/mL, respectively. The absence of difference between plasma concentrations at 2 and at 3 hr after the start of the infusion for CMS and at 3 and 4 hr after the start of the infusion of colistin indicates that steady state was attained. The results are in agreement with previously reported half-lifes of CMS and colistin in rats: 22 AE 3.4 min. and 35.5 AE 5.6 min., respectively. The experimental K p for CMS was calculated as the ratio of CMS concentration in a given tissue homogenate over its concentration of CMS in plasma at 3 hr after the start of the CMS infusion (table 3) . Similarly, the experimental K p for colistin was calculated at 4 hr after the start of the infusion of colistin sulphate (table 3) . CMS and colistin experimental K p were 28 times higher in kidneys than the average K p calculated from all other tissue. These findings indicate a potential accumulation of both compounds in the renal tissue. In vivo study. Blood samples were collected from six rats at the pre-determined time points [10] with a total of 105 observations (52 for CMS and 53 for colistin). The observed individual plasma concentration-time profiles for CMS and colistin are displayed in fig. 3 . No data below the limit of quantification (LOQ) were reported. In all animals, plasma concentrations of colistin were highest at the first sampling time (t = 5 min.), that is the formation from CMS appeared to be rapid or at the time of administration, a part of colistin was already formed.
WB-PBPK model.
The developed WB-PBPK model (figs 1 and 2) best described the time courses of CMS and colistin plasma concentrations in scenario II, as presented in the visual predictive check plots ( fig. 4 ) and individual plots (Appendix 3). The model fit of CMS concentration-time courses in scenarios I and III was satisfactory ( fig. 4) , whereas the early part of colistin plasma concentration-time profile in scenario III was not well captured by the model. The formation of colistin from CMS was adequately described estimating a common hydrolysis rate constant (k hyd-CMS ) across plasma, tissues and urine. Implementing different k hyd-CMS for plasma, tissues and urine, a time-dependent or colistin concentration-dependent k hyd-CMS did improve neither the statistical nor the graphical fit to the data. The hydrolysis was estimated to be slower in scenarios I and II as compared to scenario III (table 5) .
The model was more stable when estimating K p after grouping the tissues together (Appendix 4) with respect to their equilibrium kinetic constant (K T ) (Appendix 5). Group 1 was composed of lungs. Group 2 was composed of brain, heart, spleen, GIT and liver. Group 3 included muscle, adipose, skin and carcass. Finally, kidneys formed group 4. A separate proportionality factor (F GR ) was estimated for each group to determine K p of each single tissue (Appendix 6). Therefore, four proportionality factors were estimated for CMS and four for colistin (i.e. eight factors in total). The final grouped physiologically based PK (PBPK) model structure is displayed in Appendix 4. In scenario I, different levels of uncertainty (expressed as RSE%) in CMS and colistin K p priors have been evaluated: 10%, 25%, 50% and 100% for all tissues. Finally, a RSE of 50% was kept for the small tissues (i.e. lungs, brain, heart, spleen, GIT, liver and kidneys), whereas it was set to 25% for the large tissues (i.e. adipose, muscle, skin and carcass). The lowest uncertainty was used for K p priors of the large tissues to decrease the high influence of these tissues on tissue distribution (i.e. high physiological volumes and regional blood flows). Furthermore, K p priors calculated from the in silico model [21] apply only to passive transport processes involved in the distribution of the compound of interest. This model accounts for tissue physiological characteristics and drug protein-binding affinities. In silico and experimental K p priors of CMS and colistin are reported in table 3.
In scenario I, CMS K p estimates were similar to their priors, whereas all colistin K p estimates were higher than their priors. In scenario II, all CMS K p estimates were slightly lower than their priors, whereas the colistin K p estimate for kidneys was noticeably lower (>50%) than its prior. Except for kidneys, adipose and GIT, CMS in silico K p priors were higher than experimental K p priors. Colistin experimental K p priors were higher than the in silico ones by more than 9 times for adipose, GIT, carcass and kidneys, and by <4 times for the remaining tissues. Model-predicted K p values from scenarios I and II are presented in table 4. K p estimates for CMS were higher in scenario II than in scenario I for kidneys, adipose, GIT and carcass (1.5-16 times). As directly related to the estimated K p , volumes of distribution at steady state (V ss ) were higher for colistin (398 mL/kg in scenario I, 1021 mL/kg in scenario II and 1201 mL/kg in scenario III) than for CMS (253 mL/kg in scenario I, 267 mL/kg in scenario II and 373 mL/kg in scenario III) in all cases. Noticeably, colistin V ss estimates were higher in scenarios II and III than in scenario I (table 5) .
All clearance estimates, for both CMS and colistin, are displayed in table 5. Estimated hydrolysis clearances (CL hyd-CMS ) of CMS were similar across the different scenarios even though slightly higher in scenario III. The renal clearance (CL r-CMS ) estimate was slightly higher in scenario III than in scenario I and scenario II. Colistin non-renal clearance (CL nrcoli ) estimates were higher in scenarios II and III than in scenario I. Because high concentrations of colistin were observed at first sampling time in vivo, a fraction of colistin (F 0 ) formed from CMS prior to i.v. administration was estimated in scenarios I and II. A higher estimate of F 0 was obtained in scenario II (18.7%) than in scenario I (5.2%).
Across all scenarios, the addition of an interindividual variability (IIV) term did not improve the model fit to the data and increased model instability. A proportional residual variability model was maintained for CMS and colistin in all scenarios. The model fit was improved when CMS and colistin samples taken at the same time point were allowed to share an additive residual error term (table 5). The prediction interval width on the visual predictive check plots ( fig. 4) illustrates the residual variability which was noticeably higher for colistin in scenario III as compared to scenarios I and II. Uncertainty (RSE%) in all clearance-related parameters (i.e. Slope CMS , k hyd-CMS and k nr-coli ) was reasonable and similar across all scenarios (table 5). RSEs of K p and clearance estimates in scenarios I and II were reasonable, for both CMS and colistin.
Predictions of tissue concentrations.
The predicted unbound concentration-time courses of colistin in tissue are displayed in fig. 5 with 95% prediction intervals accounting for the RUV and uncertainty in parameter estimates. In consistent with model estimated K p values, the accumulation of colistin in renal tissue is apparent for scenarios II and III. The width of the prediction interval (grey-shaded area) around the median concentration-time course (black dashed line) is reasonable and in accordance with the estimated RUV and the RSEs of the parameter estimates.
Discussion
A WB-PBPK model was developed for colistin and its prodrug, CMS, in rat. Traditionally, PBPK models are built in a and n the number of replicates (n = 6, in this study). In silico K p priors for CMS and colistin were implemented in the WB-PBPK model with an RSE of 50% for lungs, brain, heart, spleen, GIT and liver. An RSE of 25% was implemented for adipose, muscle, skin and carcass. 2 Gastrointestinal tract. "bottom-up" fashion simulating concentration-time profiles in plasma and tissues incorporating only in vitro and/or in silico data [19, 23] . In this work, a combination of in vitro, in silico and in vivo data was utilized to construct WB-PBPK model in order to implement the prior knowledge available to describe the disposition of colistin and CMS. The PK parameters of colistin and CMS (i.e. clearances across all scenarios and K p in scenarios I and II) were estimated by fitting in vivo colistin and CMS plasma concentration-time courses. The variability in the data was quantified using a nonlinear mixed effect modelling approach, which is rarely performed in most of PBPK models published in the literature [23, 24, 28] . However, the limited number of animals used in this study did not allow the estimation of the interindividual variability.
In addition, this is one of the first studies that experimentally quantifies the distribution of CMS and colistin in various tissues using HPLC-MS/MS. Solely, a few studies have investigated colistin disposition in the epithelial lining fluid (ELF) [10, 12, 45, 46] or the cerebrospinal fluid (CSF) [47, 48] , whereas most of the studies focused on the plasma PK of these compounds [10] [11] [12] 32 ]. An old study had examined the distribution of colistin in rabbit tissues [15] but a microbiological analytical method was used to assay colistin making the interpretation of the results difficult and uncertain. The results of this study (i.e. tissue homogenates and WB-PBPK model) are complementary to increase the knowledge on the disposition of CMS and colistin and make model predictions of tissue distribution more robust in different physiological conditions or in different subpopulations.
In this analysis, K p estimates were driven by their priors in both scenarios I and II. CMS K p estimate in muscle and lungs was more than 2 times higher in scenario I than in scenario II, whereas adipose and GIT K p estimates for colistin were 4 and 7 times higher in scenario II than in scenario I, respectively. Driven by their experimental K p priors, kidney K p estimates were high suggesting an accumulation in renal tissue.
Noticeably, colistin's affinity for kidneys in scenario II was estimated to be lower (>2 times) than the experimental results. This result could be explained by the fact that the high K p priors of CMS and colistin for kidneys were due to trapped urine in the renal tissue. Moreover, non-specific binding of colistin during the experimental procedure could have caused the over-estimation of colistin (and CMS) K p priors. The derived volumes of distribution at steady state (V ss ) for CMS (table 5) were close to the extracellular fluid volume (i.e.~300 mL/kg) which is consistent with the properties of the compound not to penetrate into the cells [5] and distribute only into the interstitial fluid. Colistin V ss estimates were higher than CMS V ss across all scenarios (table 5) . The large V ss of colistin could be explained by the non-specific binding of colistin to membrane phospholipids of cells [15] and its accumulation into renal tissue [15, 28] . The WB-PBPK model estimated a similar non-renal clearance of colistin as compared to those previously reported in publications [27] . The implementation of the Fig. 4 . Visual predictive checks (VPC) of plasma concentration-time profiles for CMS and colistin in rats estimating K p using in silico K p priors (Scenario I), estimating K p using experimental K p priors (Scenario II) and fixing K p to the experimental K p prior values (Scenario III). The circles represent CMS and colistin observed plasma concentrations, the solid red line represents the median of the observed data and the yellow shaded area the 95% confidence interval of the median of the model predictions. The dashed red lines represent the 5th and 95th percentiles of the observed data, and the blue shaded areas the 95% confidence interval of the 5th and 95th percentiles of the model predictions. (12) non-renal elimination of colistin in the WB-PBPK model was based on the current knowledge of colistin PK. Except one study reporting a minor fraction of colistin undergoing glucuronidation in urine and bile [11, 32] , no published work described the mechanism of colistin clearance. Moreover, as colistin has been demonstrated to be stable in vitro at physiological temperature (37°C) for more than 96 hr [7] , it seems unlikely that spontaneous aqueous hydrolysis is its main elimination pathway. Assuming a clearance of colistin taking place in every tissue with the same rate appeared to give the best graphical and statistical fit to the data as compared to a hepatic or renal clearance. The findings on the extensive binding of colistin in tissue by Craig and Kunin [15] or laboratory material by Karvanen et al. [49] suggest that this process could explain colistin disappearance from the systemic circulation.
In scenarios I and II, the WB-PBPK model was able to describe the early peak (i.e. t max = 5 min.) of colistin in plasma. This was possible by estimating a bioavailability term [35] that represents the fraction of preformed colistin (F 0 ) which was assumed present in the arterial compartment at the time of dosing.
These estimates were higher than the values for ex vivo conversion reported in the literature (i.e. <3.5%) [50] , especially in scenario II (F 0 = 18.7%). However, because only a small fraction of CMS is converted to colistin in vivo (15.5%) [27] , the contribution of ex vivo formed colistinon in vivo concentrations of colistin is expected to be higher than 3.5% This estimate of F 0 represents in fact the fraction of colistin and/or the late-stage hydrolysis methanesulfonate derivatives in the administered solution that are able to quickly convert into colistin. Indeed, the available analytical methods do neither assay CMS as such nor methanesulfonate derivatives. CMS concentration is calculated by subtracting the actual colistin concentration to the colistin concentration after forced acidic hydrolysis of CMS [5, 6, 32] . Therefore, quantified CMS is a mixture of pure CMS and methanesulfonate derivatives at different stages of hydrolysis to colistin. Consequently, depending on the extent of the fraction of late-stage hydrolysis derivatives, the concentration peak of colistin occurs more or less rapidly. Therefore, only apparent PK parameters can be estimated for CMS [27] .
Compared to classical compartmental models, WB-PBPK models are constructed based upon the physiology and anatomy of the studied species [19, 22, 23] . These models may be used to predict concentration-time courses of antibiotics, here colistin, in target tissues. The influence of different dosing regimens and schedules, routes of administration or pathophysiological changes (e.g. anaesthetic agents, obesity, body composition and organ dysfunction) may also be predicted. Nevertheless, the development of a physiologically rational model to depict colistin's distribution in tissue is relatively more complex than it would have been for a 'simpler' molecule. Firstly, the active compound, colistin, is administered as a prodrug, CMS, raising analytical issues and difficulties to quantify CMS concentrations which are apparent concentrations [5, 6, 31] . Secondly, CMS protein binding cannot be measured experimentally due to the high chemical instability of CMS. Finally, the elimination mechanism of colistin as well as the definition of the elimination organs is so far unknown [1, 27] .
Some assumptions made during the model building process may be questioned although they were always chosen based on the current knowledge on CMS and colistin PK. Considering each tissue as a well-stirred compartment might be questionable in the cases of brain or kidneys. Model-predicted concentrations of colistin were lower in brain than in plasma which is in agreement with its physicochemical properties, that is a high molecular weight and a polycationic charge. A more detailed structure could be constructed for the brain [19] to characterize the mechanisms involved in the transport of colistin across the blood-brain barrier. To mechanistically describe the disposition of CMS and colistin in the urinary tract, the kidney tubule compartments were separated from kidney tissue compartments. The fraction of colistin formed in urine from CMS and reabsorbed into kidney tissue was fixed to the literature value, determined in an isolated perfused rat kidney model [28] . A deeper prior understanding of tubular transport of colistin is needed to refine the model structure and parametrization. Observed urine concentrations for CMS and colistin would have been informative to better describe their PK in urine. In this work, the structures of brain and kidneys were simplified to avoid model over-parametrization. As detailed earlier, CMS and colistin experimental K p priors used in this analysis were obtained from rat tissue homogenates. The risk of misleading results was minimized by a rigorous experimental procedure where attainment of steady-state plasma concentrations was ensured, all freshly excised organs were cleaned and tissue homogenization was carried out immediately on dried ice to reduce post-excision hydrolysis of CMS. The value of this experimental K p priors was confirmed by scenario II which provided the best model predictive performance and best precision in model parameters. In silico K p priors used in scenario I were not informative to predict the accumulation of colistin in renal tissue ( fig. 5 ). In this study, one of the tissue composition-based (TCB) in silico prediction models was used [21] to predict in silico K p priors. It was preferred to correlationbased methods that require in vivo data, not available for colistin and CMS [51] . The choice of a simple TCB model was also made because of the limited amount of input available for colistin and CMS and their complex chemical properties. However, the main limitation of these TCB methods is that they are based on the assumption that the distribution of the compounds is governed by passive diffusion and reversible binding, which does not fully apply in the case of colistin (i.e. non-specific binding, active transport in kidney). The use of tissue homogenates was justified by the impossibility of using microdialysis techniques for colistin. Due to its stickiness properties, a significant loss of compound was observed during experimental procedure. Several studies reported the high non-specific-binding affinity of colistin for laboratory materials [25, 52] . This was confirmed by an in-house tentative of microdialysis procedure to assay colistin in interstitial fluid of tissues. A large fraction of colistin was lost during the first hours of the experiment sticking to the laboratory material and the probe.
The final WB-PBPK models were used to predict the free concentration-time profiles of CMS and colistin in tissue in the different scenarios. The binding properties of CMS and colistin in plasma [27, 29] and tissue as well as their distribution in cells (i.e. no distribution neither in blood nor in tissue cells) were obtained from the literature and in-house experiments. Unbound predicted concentrations in tissue accounting for the RUV and uncertainty in PK parameters illustrated the robustness of model predictions with low uncertainty and variability ( fig. 5 ). In scenarios II and III, predicted tissue concentrations were highest in kidneys, which illustrates the accumulation of colistin in renal tubular cells inducing nephrotoxicity. Predictions of colistin concentrations in GIT, lung and skin are of importance for efficacy concerns.
In summary, a WB-PBPK model for CMS and colistin in rat was developed. The predictive performance of the WB-PBPK model in scenario II was best to describe observed plasma concentrations of CMS and colistin. This model has enhanced the understanding of the PK of CMS and colistin allowing for the prediction of colistin tissue distribution. The structure of the WB-PBPK model developed in this study is flexible enough to be refined and improved with inclusion of updated experimental PK data -in vitro, in silico and in vivo -for CMS and colistin. The model may be used for interspecies extrapolations using the appropriate species-specific physiological parameters and by calibrating and validating the model by fitting in vivo plasma data in the species of interest. Different approaches can be used to scale the clearances: classical allometric scaling with or without estimating the exponent parameters, with or without weighting by the maximum lifespan of the species [1] . Various methods are available to scale K p [1, 2] . Firstly, the differences in plasma and tissue binding could be accounted for which assumes that experimental data for each tissue comprised in the model is available. The second option would be to assume same binding in tissue across species and scale up K p with the unbound fraction of colistin and CMS in plasma (i.e. specific for each species) which is some species (i.e. rats, human, mice). Finally, the last option would be to use the experimental K p in rats as priors and re-estimate K p values in humans. A sensitivity approach can be used to evaluate the impact of different degrees of inflation of the prior uncertainty on model performance.
The long-term objectives were to use this model in humans combined with appropriate mechanistic PK-PD models [2] as part of a predictive framework to help optimizing drug regimens for severely ill patients infected by MDR Gram-negative bacterial infections.
